Latest Global Partnerships News

FirstWave Cloud Technology is securing $2.5 million to accelerate growth through AI-driven compliance tools and the rollout of its NMIS Cloud service with Telmex, leveraging a vast existing user base and new global partnerships.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

PainChek’s UK pilot reveals significant clinical improvements and economic benefits, positioning the digital pain assessment app for broader adoption in Scotland and beyond.

First Graphene Limited reveals significant progress in commercialising its PureGRAPH graphene technology, highlighting expanding global partnerships and a robust sales pipeline valued over A$10 million.

DTI Group Ltd reported an 11% revenue increase and secured a $4 million Adelaide Metro contract, alongside a $2.69 million capital raise to fuel growth. The company also deepened global partnerships and enhanced its technology platform during FY25.

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

Airtasker Limited reported a robust FY25 with marketplaces revenue growth accelerating to 18.3%, positive free cash flow, and significant expansion in the UK and US markets. Strategic media partnerships and brand investments underpin this momentum as the company sets sights on further growth in FY26.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

RAS Technology Holdings reports a robust 31% revenue increase in FY25, marking its second consecutive profitable year, driven by strategic acquisitions and global partnerships that position it for sustained growth.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.